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TO THE EDITOR
As a biomedical researcher, albeit in a
long-gone, pre-geriatric existence, I
was more saddened than involved by
the Stossel/Williams spat (Stossel, 2007;
Williams, 2007), because theirs isn’t a
conflict: the boys are having a phoney
war with wooden swords and paper
hats. But it is now past bedtime, the toys
can be put away and grandpa will have
to tidy up.
Of course lots of people get fame
and fortune from papers, lectures and
opinion-leadering; and of course this
influences what they do and say (pace
Stossel); and of course public self-
exposure will make no difference (pace
Williams). But you can forget the
wooden swords and paper hats, be-
cause, absurd though it may be, the
intellectual flashing of ‘COI’ now has to
be tolerated––just as my generation had
to tolerate the inquisitorial baring of
souls to ethical committees, despite
their irrelevance to, and inhibition of,
research (Shuster, 1979). Medical his-
tory will record the titillating scandal of
an ethical committee spawning a bas-
tard offspring, the COI.
So my response to the pro- and anti-
COI flashers is a curse on both your
palaces. The real problem is the almost
complete absence of real biomedical
research; and, sadly, most people be-
lieve the recyclable rubbish now pro-
duced (the inane trials and correlative
epidemiology done outside the labs,
and the pointless technology, such as
gene fishing, done within them) is the
real thing.
This ‘conflict’ is as irrelevant as Aunt
Sally’s dead husband: all that matters is
the quality of research, and I don’t give
a toss whether Watson and Crick were
being secretly supported by God, the
Devil or both.
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TO THE EDITOR
We write to respond to points raised by
Dr Rees in the recent editorial ‘‘The
Nature of Clinical Evidence: Floating
Currencies Rather than Gold Stan-
dards’’ (Rees, 2007).
We agree with Dr Rees that change
is the only constant (Heraclites, c. 475
BC) in clinical evidence, that clinical
decisions should be based on the best
available evidence (Collier et al.,
2006), and that randomized controlled
trials (RCTs) are not always necessary
(Glasziou et al., 2007). Furthermore,
the results of single RCTs, even when
published in highly prestigious journals,
can be hazardous when read in isola-
tion (Ioannides, 2005), highlighting the
need for systematic reviews of all
available RCTs. Rees points out that
RCTs should not be blindly regarded as
a ‘‘fixed’’ gold standard. We agree.
While RCTs offer the strongest design to
minimize bias in human intervention
studies, their quality (in terms of design,
conduct, analysis, reporting, and rele-
vance) is highly variable, furthering
the argument for systematic reviews
to draw attention to such multidi-
mensional components (Bigby, 2003;
Williams, 2003).
Because systematic reviews are
the most cited form of clinical litera-
ture (Patsopoulos et al., 2005), if one
accepts citation impact as a measure of
importance, we disagree that the im-
portance of systematic reviews has
‘‘never been subject to experimental
study’’ (Rees, 2007). Systematic reviews
of all available evidence are also the
main source of evidence used by the UK
National Institute of Health and Clinical
Excellence (http://www.nice.org.uk/)
and the US Agency for Healthcare
Research and Quality (http://www.
ahrq.gov/) to inform health policy.
We agree with Rees that there is
increasing awareness that ‘‘failure to
report studies may lead to error’’ (Rees,
2007). For example, the concealment of
serious cardiovascular adverse events
for rofecoxib made a significant differ-
ence to the positive light thrown on the
drug from other trials at that time
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Abbreviation: RCT, randomized controlled trial
(Krumholz et al., 2007). When the truth
of the real risks emerged, the drug was
withdrawn. Systematic reviews serve to
foster such enlightenment.
We agree with Rees’ description of
P-values as indicating false positive
error rates when used in the context of
elementary frequentist statistical theory.
We still maintain, however, that one of
the advantages of systematic reviews is
that they can improve the precision of
estimates derived from smaller similar
trials, thus making lots of additional
trials unnecessary when an acceptable
level of false positive error has been
reached. To date, 14 placebo-con-
trolled trials of topical pimecrolimus
for atopic eczema have been con-
ducted – do we really need any more
to convince the clinical community that
pimecrolimus is effective when com-
pared to vehicle? A more serious
example is the use of intravenous
streptokinase as thrombotic therapy for
myocardial infarction. By performing a
cumulative meta-analysis of similar
RCTs, Lau et al., (1992) showed clear
and consistent benefit for streptokinase
after just eight RCTs involving 2,432
patients had been performed in 1973.
Yet by 1988, a further 25 RCTs invol-
ving another 35,542 patients had been
performed in isolation addressing the
same question without altering the
risk estimate, but making the overall
P-value very small indeed (Po0.0001).
Such an observation illustrates the hu-
man cost of failing to observe the need
to bring all evidence together within the
body of a systematic reviews, as op-
posed to wasting valuable patient and
doctor resources in continuing to per-
form one inconclusive trial after an-
other. There comes a point when the
likelihood of a false positive results
becomes very remote, and even
the most skeptical person would say
‘‘enough is enough’’.
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TO THE EDITOR
Non-bullous congenital ichthyosiform
erythroderma (NBCIE; OMIM 242100)
is a rare, autosomal recessive disorder
characterized by prominent erythroder-
ma and fine, white, superficial scales.
Mutations in the transglutaminase 1
gene (Laiho et al., 1997; Akiyama
et al., 2001; Becker et al., 2003), the
12R-lipoxygenase gene, the lipoxygen-
ase-3 gene (Jobard et al., 2002), ichthyin
(Lefe`vre et al., 2004), and FLJ39501
(Lefe`vre et al., 2006) have been identi-
fied as causal in human NBCIE.
Recently, mutations in the gene en-
coding the adenosine triphosphate-bind-
ing cassette transporter protein ABCA12
(OMIM 607800) have been reported
to cause type II lamellar ichthyosis (LI;
OMIM 601277) (Lefe`vre et al., 2003)
and harlequin ichthyosis (OMIM
242500) (Akiyama et al., 2005; Kelsell
et al., 2005). Until now, only a few
cases of autosomal recessive congenital
Abbreviations: LI, lamellar ichthyosis; NBCIE, non-bullous congenital ichthyosiform erythroderma;
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